PL4531816T3 - Formulacje farmaceutyczne biktegrawiru oraz lenakapawiru - Google Patents
Formulacje farmaceutyczne biktegrawiru oraz lenakapawiruInfo
- Publication number
- PL4531816T3 PL4531816T3 PL24755477.7T PL24755477T PL4531816T3 PL 4531816 T3 PL4531816 T3 PL 4531816T3 PL 24755477 T PL24755477 T PL 24755477T PL 4531816 T3 PL4531816 T3 PL 4531816T3
- Authority
- PL
- Poland
- Prior art keywords
- lenacapavir
- bictegravir
- pharmaceutical formulations
- formulations
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363519675P | 2023-08-15 | 2023-08-15 | |
| EP23201068.6A EP4529922A1 (en) | 2023-09-29 | 2023-09-29 | Pharmaceutical formulations of bictegravir and lenacapavir |
| PCT/US2024/042251 WO2025038715A1 (en) | 2023-08-15 | 2024-08-14 | Pharmaceutical formulations of bictegravir and lenacapavir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4531816T3 true PL4531816T3 (pl) | 2026-04-27 |
Family
ID=92626506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL24755477.7T PL4531816T3 (pl) | 2023-08-15 | 2024-08-14 | Formulacje farmaceutyczne biktegrawiru oraz lenakapawiru |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20250073172A1 (pl) |
| EP (2) | EP4531816B1 (pl) |
| KR (1) | KR20260052994A (pl) |
| CN (1) | CN121712492A (pl) |
| AU (1) | AU2024325153A1 (pl) |
| ES (1) | ES3064824T3 (pl) |
| PL (1) | PL4531816T3 (pl) |
| SI (1) | SI4531816T1 (pl) |
| TW (1) | TW202513072A (pl) |
| WO (1) | WO2025038715A1 (pl) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2893843C (en) | 2012-12-21 | 2018-09-04 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| TW202138365A (zh) | 2016-08-19 | 2021-10-16 | 美商基利科學股份有限公司 | 治療性化合物 |
| EP4643882A3 (en) * | 2019-11-26 | 2026-01-14 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
-
2024
- 2024-08-14 EP EP24755477.7A patent/EP4531816B1/en active Active
- 2024-08-14 ES ES24755477T patent/ES3064824T3/es active Active
- 2024-08-14 WO PCT/US2024/042251 patent/WO2025038715A1/en active Pending
- 2024-08-14 SI SI202430016T patent/SI4531816T1/sl unknown
- 2024-08-14 KR KR1020267007625A patent/KR20260052994A/ko active Pending
- 2024-08-14 EP EP25223872.0A patent/EP4725552A2/en active Pending
- 2024-08-14 PL PL24755477.7T patent/PL4531816T3/pl unknown
- 2024-08-14 AU AU2024325153A patent/AU2024325153A1/en active Pending
- 2024-08-14 TW TW113130410A patent/TW202513072A/zh unknown
- 2024-08-14 US US18/804,677 patent/US20250073172A1/en active Pending
- 2024-08-14 CN CN202480053250.3A patent/CN121712492A/zh active Pending
-
2025
- 2025-11-07 US US19/382,753 patent/US20260060934A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025038715A1 (en) | 2025-02-20 |
| SI4531816T1 (sl) | 2026-04-30 |
| ES3064824T3 (en) | 2026-04-29 |
| EP4531816A1 (en) | 2025-04-09 |
| EP4725552A2 (en) | 2026-04-15 |
| CN121712492A (zh) | 2026-03-20 |
| KR20260052994A (ko) | 2026-04-20 |
| EP4531816B1 (en) | 2025-12-31 |
| US20250073172A1 (en) | 2025-03-06 |
| TW202513072A (zh) | 2025-04-01 |
| US20260060934A1 (en) | 2026-03-05 |
| AU2024325153A1 (en) | 2026-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2611642B (en) | Pharmaceutical and cosmetic compositions comprising secretomes | |
| IL316049A (en) | Musuntuzumab pharmaceutical preparations and methods of use | |
| IL316170A (en) | Pharmaceutical compositions of therapeutic proteins and methods of use | |
| IL326514A (en) | Pharmaceutical formulations of GRP119 agonists and their uses | |
| IL314952A (en) | Pharmaceutical preparation containing diphenyldiazole history and methods of use | |
| IL316562A (en) | High-dose and convenient formulations of endoxifen | |
| IL286416A (en) | Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration | |
| SI4531816T1 (sl) | Farmacevtske formulacije biktegravirja in lenakapavirja | |
| ZA202109296B (en) | Formulations and preparations for prevention and treatment of covid-19 and flu therefor | |
| IL319382A (en) | Pharmaceutical preparation and its use | |
| CA3300004A1 (en) | Pharmaceutical formulations of bictegravir and lenacapavir | |
| HK40122888A (en) | Pharmaceutical formulations of bictegravir and lenacapavir | |
| PT4531816T (pt) | Formulações farmacêuticas de bictegravir e lenacapavir | |
| HK40121460A (en) | Pharmaceutical compositions of mosunetuzumab and methods of use | |
| CA3304242A1 (en) | Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses | |
| GB202408903D0 (en) | Pharmaceutical compositions and medical uses | |
| ZA202212702B (en) | Pharmaceutical formulations and their preparations for treatment of cancer | |
| IL312915A (en) | Solid forms of reziquimod and their formulations | |
| GB202212656D0 (en) | An orodispersible tablet of fecofenadine and it process of preparation | |
| IL327411A (en) | Pharmaceutical preparations containing maralicife and their uses | |
| CA3278196A1 (en) | Liquid oral formulations of netupitant and palonosetron | |
| AU2023421785A1 (en) | Liquid oral formulations of netupitant and palonosetron | |
| HK40131600A (en) | Pharmaceutical formulations and uses thereof | |
| HK40123008A (en) | High dose endoxifen formulations and methods of use | |
| GB202212240D0 (en) | New formulations and medical uses thereof |